Why Nike Shares Are Sinking Today

Nike downgraded by Oppenheimer analyst, amid the company's plan to cut 1,600 jobs to save costs. The analyst expects top-line trends at the enterprise to remain sluggish and below algo in the next several quarters.

Oppenheimer analyst downgraded Nike Inc (NYSE:NKE) to Perform from Outperform and lowered the price target to $110 (from $150). 

Also, the company reportedly plans to reduce over 1,600 jobs to enhance focus on key categories like running and women’s apparel.

This is at par with the company’s aim to deliver up to $2 billion in cumulative cost savings during the next three years.

The analyst expects top-line trends at the enterprise to remain sluggish and below algo in the next several quarters.

The analyst cited several concerns, including spotty consumer demand, pauses in product innovation, and modest competitive incursions in select categories. 

For the third quarter (Feb), the analyst lowered EPS estimates to $0.74 (from $0.96) vs. consensus of $0.76, with currency-adjusted revenue growth projected to be down 0.7% (from +5% earlier). 

For FY26 (May), the analyst cut EPS estimates to $4.57 (from $5.20) vs. consensus of $4.95 and expects currency-adjusted sales expansion of +5%-7%. 

Price Action: NKE shares are trading lower by 3% at $102.87 on the last check Friday.

Image: Shutterstock/ pio3

Total
0
Shares
Related Posts
Read More

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment In Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes In Poster Presentation At WCIRDC

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt Week 26, 22 weeks after the last dose of BMF-219, participants in the 100

BMEA